DOJ Ends Abbott Baby Formula Criminal Probe After Evidence Review: WSJ
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
abbott-laboratoriesdoj-investigation
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Federal prosecutors have concluded a criminal investigation into Abbott Laboratories concerning a Michigan infant formula plant's 2021 shutdown and subsequent nationwide shortage, according to a Wall Street Journal report. The Department of Justice decided not to pursue charges following a review of evidence compiled by the Food and Drug Administration. The closure of the probe removes a significant legal liability for one of the country's largest formula manufacturers.
The DOJ's decision arrives as the US baby formula market shows signs of stabilization after the 2021-2022 crisis. Abbott's Sturgis, Michigan facility, which produces Similac and other specialty formulas, was shut down in February 2022 following FDA inspections that revealed bacterial contamination. The shutdown exacerbated a supply chain crisis, leading to nationwide out-of-stock rates exceeding 70% by May 2022. The DOJ's probe examined whether Abbott executives provided false or misleading statements to regulators regarding plant conditions.
Historically, corporate resolutions with the DOJ often involve deferred prosecution agreements or significant fines. In 2015, ConAgra Foods pleaded guilty and paid an $11.2 million penalty for shipping Salmonella-contaminated peanut butter. The decision to close the Abbott probe without action is a notable departure from this pattern given the scale of the public health impact. The current macro backdrop includes heightened regulatory scrutiny on consumer product safety and corporate accountability.
Abbott's nutritional division, which includes baby formula, generated $7.5 billion in sales during fiscal year 2025. The segment represents approximately 22% of the company's total revenue. The 2022 plant shutdown contributed to a 12% year-over-year decline in US pediatric nutritional sales in the second quarter of that year.
| Metric | Pre-Shutdown (Q4 2021) | Post-Reopening (Q4 2023) |
|---|---|---|
| US Baby Formula Market Share | ~42% | ~39% |
| Abbott Nutritional Segment Operating Margin | 18.5% | 16.8% |
The company has invested over $500 million in upgrades to the Sturgis facility since its reopening. Abbott's chief competitor, Reckitt Benckiser's Enfamil brand, saw its market share increase to approximately 35% during the shortage period, up from a pre-crisis 31%. Abbott's stock price is up 14% year-to-date, slightly lagging the S&P 500 Health Care sector's 16% gain.
The closure of the criminal probe is a clear positive for Abbott Laboratories (ABT), removing a major litigation overhang that had weighed on investor sentiment. The decision reduces the risk of substantial financial penalties and allows management to focus fully on operational execution. This development is likely to benefit other large-cap consumer health names like Perrigo (PRGO), a private-label formula manufacturer, by reinforcing a perceived lower regulatory risk profile for the sector.
A counter-argument is that civil litigation and ongoing FDA oversight remain material risks for Abbott. Multiple wrongful death lawsuits linked to the contaminated formula are still pending. Investor positioning had been cautiously optimistic, with short interest in ABT declining by 18% over the past six months in anticipation of a favorable resolution. The news may trigger inflows into the Health Care Select Sector SPDR Fund (XLV) as regulatory fears subside.
The primary catalyst for Abbott is its Q2 2026 earnings report, scheduled for July 20, 2026. Management's commentary on margin recovery in the nutritional segment will be critical. Investors should monitor the FDA's inspection reports for the Sturgis facility, with the next routine inspection expected in Q3 2026.
Key levels to watch for ABT stock include a resistance zone around $128, representing the 52-week high. A sustained breakout above this level on high volume would signal strong conviction in the legal resolution. The next major regulatory event for the industry is the FDA's deadline for implementing new infant formula oversight rules, set for December 2026. For broader market context, track the performance of the S&P 500 Consumer Staples index relative to the health care index.
The removal of a potential criminal indictment eliminates a significant downside risk, likely leading to a reassessment of the company's valuation by institutional investors. Analysts may revise their discounted cash flow models to reflect a lower litigation risk premium, potentially adding $3-$5 to fair value estimates. The stock had underperformed peers due to this legal uncertainty, a gap that may now close.
The outcome contrasts with historical precedents like the ConAgra case, where a guilty plea was secured. A closer parallel is the FDA's 2016 criminal investigation into Mead Johnson over alleged contamination, which also concluded without charges. The Abbott case was unique due to its direct contribution to a national shortage, suggesting the DOJ's evidential threshold for prosecution was exceptionally high.
Abbott still faces substantial civil litigation from families who allege their children were sickened by contaminated formula. These wrongful death and personal injury suits represent a multi-billion dollar liability, though they are typically settled for lesser amounts. The company also remains under a FDA consent decree for the Sturgis plant, requiring strict adherence to safety protocols under threat of severe penalties.
The DOJ's decision closes a major legal chapter for Abbott, shifting focus back to operational execution and margin recovery.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.